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Polymeric IgA and immune complex concentrations in IgA-related
renal disease. Polymeric IgA (PIgA) and immune complex concentra-
tions in IgA-related renal disease were measured in cross sectional and
longitudinal studies to establish the relationship between these param-
eters and both mucosal infection and renal dysfunction. These studies
were performed in 50 patients with IgA nephropathy (IgAN), 17
patients with Henoch Schdnlein purpura nephritis (HSPN), 11 control
patients with IgA negative, diffuse mesangial proliferative glomerulo-
nephritis (DMPGN) and 50 healthy controls. Total PIgA (PIgA) and
PIgA subclass concentrations were measured using a secretory compo-
nent binding enzyme immunoassay and isotype specific immune com-
plex concentrations were measured using conglutinin (K) binding
immunoassays. In cross sectional studies patients with IgAN were
found to have increased concentrations of PIgA, PIgA1, K-IgA1 and
K-IgA2 compared to controls. In the longitudinal studies controls and
patients had significant increases in PIgA-,. and PIgA1 concentrations
during infection. However, in patients with IgAN, the increases were
greater, persisted for longer, and PIgA2 concentrations were also
increased. K-IgA, and K-IgA2 concentrations increased significantly
during episodes of infection in IgAN patients in contrast to controls.
Patients with HSPN had results similar to those of IgAN patients. No
significant correlation was found between PIgA or K-IgA concentra-
tions, and either serum creatinine concentrations or the degree of
hematuria. The results indicate that patients with IgA-related renal
disease have abnormal regulation of PIgA and immune complexed IgA,
and that these abnormalities are exaggerated during mucosal infection.
Mesangial IgA nephropathy (IgAN) and Henoch-Schonlein
nephritis (HSPN) are considered to be IgA immune complex
deposition diseases [1—5]. A murine model of IgAN in which
hematuria was induced demonstrated that immune complexes
containing polymeric IgA (PIgA) were deposited in the glomer-
ular mesangium, but that immune complexes containing the
same monomeric antibody and the same antigen were not
deposited [6]. Early human studies suggested the mesangial IgA
deposits contained PIgA by demonstrating that secretory com-
ponent bound to the deposits [7—9] and that J-chain was present
in the mesangial deposits even in the absence of 1gM [8, 10, 11].
Recent studies employing the molecular sizing of immunoglob-
ulin eluted from renal tissue confirmed the presence of PIgA in
the mesangial deposits in IgAN [12, 13]. Serum PIgA concen-
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trations are also increased in patients with IgAN and HSPN
[14—16]. Sancho, Egido and Gonzalez [17] have described
increased concentrations of PIgA-containing immune com-
plexes in patients with IgAN. The presence of increased num-
bers of PIgA producing cells was also demonstrated in the blood
of patients with higher urine red blood cell (RBC) counts [18].
The origin of the mesangial PIgA is unknown. The vast
majority of PIgA producing cells are found in mucosal associ-
ated lymphoid tissue. In normal humans serum PIgA is pro-
duced in response to mucosal and parenteral antigen challenge
[19—21]. The IgA response is initially dominated by PIgA
production but monomeric IgA becomes dominant later [20,
21]. In patients with IgAN mucosal infections often precipitate
exacerbation of hematuria and occasionally renal impairment
[22].
The aim of this study was to estimate concentrations of serum
PIgA and serum IgA immune complexes in patients with IgAN
and HSPN under conditions of mucosal infection and freedom
from such infection to determine whether these conditions
provided a pathogenic link between the clinical events of
mucosal inflammation and disease exacerbation. The study was
divided into a cross sectional study involving all patients
enrolled, and a longitudinal study of those patients and controls
followed over the course of a mucosal infection in a prospective
manner.
Methods
These studies were performed following approval from the
Medical Ethics Committees, Royal Children's Hospital and
Royal Melbourne Hospital, and informed consent was obtained
from all patients and controls.
Patients and sample collection
Fifty patients with biopsy proven IgAN (33 males, 17 fe-
males; aged 8 to 42, median 23 years), 17 patients with HSPN (8
males, 9 females; aged 6 to 35, median 16 years), 11 control
patients with IgA-negative diffuse mesangial proliferative gb-
merulonephritis (DMPGN, 5 males, 6 females; aged 18 to 35,
median 26 years), and 50 healthy controls (26 males, 24 females,
aged 16 to 45, median 24 years) were enrolled in the study.
Cross sectional studies were performed on samples collected
from patients and controls on enrollment in the study, provided
that the subjects had no infection at the time. Longitudinal
studies during the course of a mucosal (upper respiratory tract
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in all cases apart from one gastrointestinal) infection were
performed prospectively. All patients were reviewed every six
to ten weeks, and samples of serum and midstream urine (MSU)
were collected. When the patients or controls developed symp-
toms of an infection they were asked to notify the study
immediately. They were examined that day, and an infection
was confirmed if there was an oral temperature of greater than
38°C, upper respiratory tract mucosal inflammation, or bacte-
riological (tonsil swab) or virological (post nasal mucus culture)
evidence of infection. The first day of infection was defined as
the day on which the onset of symptoms could be clearly
recalled. The patients had morning fasting serum and MSU
samples collected on three occasions during the period of
infection: when first seen (days 1 to 3), and then between days
four and six, and days seven to ten following the onset of
symptoms. The patients were then reviewed 6 to 12 weeks later,
and further serum and MSU samples collected. Altogether, 21
patients with IgAN, 11 patients with HSPN, 2 patients with
DMPGN and 15 controls were studied during an episode of a
mucosal infection.
Measurement of PIgA concentrations
The relative total serum PIgA (P1gA) and PIgA subclass
(PIgA1 and PIgA2) concentrations were estimated using a novel
immuno-assay assay [23]. Briefly, purified human secretory
component was passively adsorbed to the surface of the immu-
noplate wells. Duplicate serum samples were adsorbed with
Sepharose bound goat antihuman 1gM to prevent competition
between 1gM and PIgA for binding to secretory component, and
then the sera were diluted and added to the immunoplate wells.
Peroxidase conjugated goat antihuman IgA antisera was added
in the third step of the assay, and followed by the addition of
orthophenylene diamine substrate. The subclass assays utilized
the addition of monoclonal anti-IgA subclass antibodies after
the sample incubation step, followed by peroxidase conjugated
goat antimouse IgG antisera and then substrate. The assays
were quantitated against serial titrations of human IgA1 and
IgA2 myeloma sera and the results were expressed with respect
to the concentrations of these proteins. Control and myeloma
reference sera were included on all immunoplates. The interas-
say coefficients of variation for the PIgA, PIgA1 and PIgA2
immunoassays were 12, 9 and 12%, respectively.
The nature of the polymeric lgA detected has been previously
reported [23]. The proportion of total serum IgA detected was
0.5 to 2.0%, a value similar to others reported using solid phase
secretory component binding techniques [24, 25]. Monomeric
IgA, heat aggregated monomeric IgA, colostral IgA and sali-
vary IgA did not bind to secretory component or cause inter-
ference in the assays.
Conglutinin binding im,nune complex assays
Conglutinin was isolated using the method of Lachmann and
Hobart [26], modified by using pepsin digestion as described by
Maire, Barnet and Lambert [27]. Enzyme immunoassays
(EIAs) were developed, by modifying the method of Doi et al
[28], to measure concentrations of conglutinin binding total IgA
(K-IgA), K-IgA1, K-IgA2, K-IgG and K-IgM. Ninety-six well
microtiter plates (Immunoplate 1, Nunc, Kamstrup, Denmark)
were coated with conglutinin by incubation of 100 jsl of con-
glutinin (2.5 sgIml) in 0.06 M carbonate buffer, pH 9.6, for three
hours at 37°C and overnight at 4°C. The plates were washed
three times between subsequent steps with Veronal buffered
saline (0.14 M NaCl, 5 sM sodium diethylbarbiturate, 0.15 mr'i
CaCl2, 1.0 mi MgCl2) containing 0.05% Tween 20 (VBS-Tw).
After blocking with 100 d of VBS-Tw containing 2% human
serum albumin for one hour at 37°C, 50 1d of serum samples
diluted 1 in 10 in VBS-Tw were incubated, in duplicate, for two
hours at 37°C. Either 50 pJ of peroxidase conjugated affinity-
purified goat antihuman IgA F(ab)2, IgG or 1gM antisera (Tago
mc, Burlingame, Vermont, USA), or murine monoclonal anti-
human IgA1 or antihuman IgA2 antibody (clones 1-155-1 and
14-3-26, respectively, Becton Dickinson Immunocytometry
Systems, Mountain View, USA), at the appropriate dilution
[23] in VBS-Tw containing 2% bovine serum albumin (VBS-dil)
were incubated at 37°C for two hours. Following use of the
monoclonal antibodies, 50 d of peroxidase conjugated goat
antimurine IgG in VBS-dil were added for two hours at 37°C.
After washing. 50 d of 0.06 M citrate phosphate buffer contain-
ing orthophenylene diamine and 0.003% H202 were added for
15 minutes. The reaction was ended by addition of 25 pi of 4 N
H2S04 and the absorbance was quantitated at 492 nm using a
Titertek Multiscan (Flow Laboratories Ltd., Scotland, UK).
The complement and calcium dependence of the assays were
confirmed using the method described by Casan et al [29]. Each
assay was quantitated in relative units [30] with respect to the
duplicate serial titrations of a serum which had been found to
have high concentrations of conglutinin binding immunoglobu-
tin (K-Ig). The means of these absorbances were used to
construct a curve of absorbance versus dilution of the reference
serum and test sample absorbances were read against this
curve. A relative unit value of 100 was assigned to a dilution of
the reference serum that had a value near the upper end of the
sigmoidal reference curve. For the K-1gA, K-IgA1, K-IgA2,
K-lgG and K-IgM assays the intraassay coefficients of variation
were 3, 5, 5, 4 and 4%, respectively, and the interassay
coefficients of variation were 14, 18, 20, 9 and 9%, respectively.
Microbiological cultures and MSU examinations were per-
formed by the Microbiology Department of the Royal Chil-
dren's Hospital, Melbourne. Serum creatinine concentrtions
were estimated by the Biochemistry Department of the Royal
Children's Hospital, using a Kodak Ektachem 700 Analyzer.
Statistical analyses
Statistical evaluation was performed on an IBM personal
computer, using Minitab (University of Pennsylvania). For
comparisons between independent groups, the Chi-square test
and the Mann-Whitney U test were performed. For comparison
of a parameter's value within a group over a period of time, the
Sign test was used. A P value of 0.05 or less was taken as
significant. Correlations were sought using the Spearman rank
order correlation test.
Results
Cross sectional studies in the absence of infection
No correlation between age and any of the PIgA or K-IgA
assay results was found in any of the control or patient groups.
1. Concentrations of PIgA. The concentrations of PIgA,
PIgA1 and PIgA2 when patients and controls were well and free
from infection or disease exacerbation are shown in Figure 1,
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together with P values for comparisons between groups where
a significant difference was found.
2. Concentrations of conglutinin binding immune complexes.
The concentrations of K-IgA, K-IgA, and K-IgA2 in the same
samples on which PIgA measurements were performed are
shown in Figure 2. All test samples had detectable concentra-
tions of IgA and IgA1 binding to conglutinin. However, 46% of
controls, 55% of patients with DMPGN, 32% of patients with
IgAN and 43% of patients with HSPN had no detectable IgA2
binding to conglutinin.
There were no significant differences between the groups
with regard to K-IgG and K-IgM concentrations.
The number of patients having a result gi ..ater than the 95th
centile of the control group was significant in both the IgAN and
HSPN groups for K-IgA ( = 18.3, P < 0.0001, and = 20.0,
P < .0001, respectively) and K-IgA1 ( = 12.8, P < 0.0005,
and = 4.5, P < 0.05, respectively), and in the IgAN group for
K-IgA2 (y = 4.6, P < 0.05).
3. Correlation between K-lgA concentrations and PIgA con-
centrations. The correlations between PIgA and K-IgA were
significant for patients with IgAN and patients with HSPN,
although the r values were low. The rank order correlations for
PIgA and K-IgA concentrations were: for IgAN patients N
50, r = 0.34, P = 0.01; for HSPN patients N = 17, r = 0.42,
P < 0.05; for controls N = 50, r 0.18, P > 0.05; and for
DMPGN patients N = 11, r, = 0.3, P> 0.05. No significant
correlation was found between PIgA subclass concentrations
and K-IgA subclass concentrations in the other groups.
Studies during the course of upper respiratory tract
mucosal infection
The two control patients with DMPGN followed during a
mucosal infection had results close to the modal results for the
healthy control group and, as the results of the cross sectional
data revealed the two groups were similar with regard to these
parameters, the results have been included with those of the
control group. The infective agents, where identified microbio-
logically, are listed in Table 1.
The number of infections due to any one specific microbio-
logical cause was small, but no trend was noted for the PIgA or
K-IgA immune response to differ with regard to bacterial or
viral etiological agents.
1. Concentrations of PIgA within each group during infec-
tions. The concentrations of PIgA before infection, at the three
sequential periods during infection and after infection are
shown in Figure 3. The sequential changes in the PIgA concen-
trations have been evaluated using the Sign test in Table 2.
Within the control group concentrations of PIgA and PIgA1
increased from the preinfection time to the period four to six
days following infection and then decreased to the period 6 to 12
weeks following infection.
Within the IgAN group concentrations of PIgA and PIgA1
increased from before infection to all periods during infection
reaching a maximum found seven to ten days after the onset of
infection. Concentrations of PIgA2 increased from before infec-
tion to all times during infection, and the median value was
highest one to three days after the onset of infection. The
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Fig. 1. Cross sectional study of total PIgA (PIgA), PIgA, and PIgA2 concentrations in patients with IgAN (IgA, N = 50), controls (C, N = 50),
HSPN (HSP, N = 17), and DMPGN (N = 11) in the absence of infection. The arrows represent the median values. The results for the groups were
compared using the Mann-Whitney U test, and significant differences between the groups are indicated.
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Table 1. The results of microbiological investigations of the causes
of the mucosal infections in the longitudinal study
Number of isolations in each patient
group
Control IgAN HSPN
Infective organism (N = 17) (N = 21) (N = Il)
Parainfiuenza viruses 1 1 1
Enterovirus I
Rhinovirus 1 2 3
Influenza A virus 1
Influenza B virus 1
Campylobacter jejuni 1
Group A, beta-hemolytic 3 1
streptococcus
qualitative nature of the changes in PIgA and PIgA1 concen-
trations within the HSPN group were similar to those found in
patients with IgAN.
2. Comparison of PIgA concentrations between the patient
and control groups during infection. Concentrations of PIgA
and PIgA1 were higher in the patients with IgAN than in the
control group at all times before, during and after infection
(Mann Whitney U test, P < 0.05 for all time periods). The
maximum difference was found seven to ten days following
onset of infection for PIgA concentrations, and at four to six
days following onset of infection for PIgA1 concentrations. No
significant difference in PIgA2 concentrations was found be-
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tween patients with IgAN and controls, despite the significant
rise in PIgA2 concentrations within the IgAN group.
The IgAN and HSPN groups had similar time related changes
in concentrations of PIgA. No significant differences were
found at any time between these two groups. Likewise, no
significant difference was found between the PIgA concentra-
tions for the patients with HSPN and the control group at any
time, despite the increased PIgA concentrations found in the
cross sectional studies in the HSPN group (where there were
greater control and HSPN patient numbers). However, a sig-
nificant difference in PIgA1 concentrations was found in the
periods four to six days, seven to ten days and 6 to 12 weeks
following onset of infection in the HSPN group compared to the
control group (P < 0.05 for each case).
3. Concentrations of K-Ig within each group during infec-
tions. The data for each assay are displayed in Figure 4. The
significance of the K-IgA concentration changes has been
tabulated (Table 3).
Conglutinin binding immunoglobulin concentrations re-
mained fairly constant within the control group, although a
significant decrease in K-IgA concentrations was found be-
tween 7 and 10 days following onset of infection and 6 to 12
weeks after infection.
Within the IgAN group K-IgA, K-IgA1 and K-IgA2 concen-
trations increased to highest median concentrations one to three
and four to six days following the onset of symptoms. K-IgG
concentrations increased from prior to infection to the time four
to six days following the onset of infection (P < C.05), and
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Fig. 2. Cross sectional study of K-IgA, K-IgA1 and K-IgA2 concentrations in the patient groups in the absence of infection. The 95th centiles for
the results for the control group (C) are indicated by the single horizontal lines. The double horizontal line (for K-IgA2 results) indicates the lower
limit of sensitivity of the assay. The results for the groups have been compared using the Mann-Whitney U test (results shown in the figure), and
Chi-square test for the number of patient results above the 95th centile of the control group (results are in the text).
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Fig. 3. Longitudinal study of P1gA (P1gA), PIgA, and PIgA2 con-
centrations during a mucosal infection. The times of sampling are
indicated by B (6—12 weeks before infection); 1, 2, 3 (1—3 days, 4—6
days, and 7—10 days following the onset of infection, respectively), and
A (6—12 weeks after the onset of infection). The 25th, median, and 50th
percentile values are indicated by the lower, middle and upper horizon-
tal bars, respectively, at each time interval. The groups are controls (N
= 17), patients with IgAN (N = 21) and patients with HSPN (N = 11).
decreased from four to six days following onset of infection to
the periods seven to ten days following onset of infection and
six weeks following infection (P < 0.05 for each case).
The K-IgA concentrations within the HSPN group were
maximal seven to ten days following the onset of infection.
K-IgM concentrations decreased between four and six days
following onset of infection and six weeks post-infection (P <
0.05).
4. Comparison of K-IgA changes between patient and control
groups during infection. A significantly lower concentration of
K-IgA was found in the control group compared to that found in
the IgAN and HSPN groups at all times (Mann Whitney U test,
P < 0.01 for K-IgA, and P < 0.05 for K-IgA1 and K-IgA2 at
each time).
The changes in K-IgA, K-IgA1 and K-IgA2 concentrations
were significantly greater for the periods one to three and four
to six days following the onset of infection in patients with
IgAN compared to those of the control group (P < 0.05 in each
case). The changes in K-IgA concentrations were also signif-
icantly greater in patients with IgAN than in patients with
HSPN (P <0.01) for the time one to three days following the
onset of infection, but not later. This reflects the slower rise in
K-IgA concentrations seen in the HSPN group (Fig. 4).
The changes in K-IgA1 concentrations were significantly
greater in HSPN patients than controls for the times one to
three, four to six and seven to ten days following the onset of
infection (P < 0.05 in each case), although similar results were
not found for K-IgA or K-IgA2 concentrations.
5. Correlation between PIgA, KIgA, MSU RBC counts, and
creatinine. In the cross sectional studies no significant correla-
tions were found between either PIgA or K-IgA concentrations,
and either MSU RBC counts or serum creatinine concentra-
tions. During mucosal infection every patient with IgAN,
HSPN and DMPGN had an increase in MSU RBC counts and
all had increases in serum K-IgA and serum PIgA concentra-
tions. However, the correlation between MSU RBC counts and
either PIgA or KIgA was significant in only a few patients. Of
the 21 patients with IgAN patients followed during infection,
two had a significant correlation between PIgA and MSU RBC
counts, and five had a correlation between KIgA and MSU
RBC counts. For the 11 HSPN patients the correlations were
both significant in three patients. MSU RBC counts were
highest at one to three days after the onset of symptoms in all
except four patients with IgAN and four patients with HSPN
patients.
Discussion
The principal findings of this study were that patients with
IgA-related renal disease had abnormally increased serum
concentrations of polymeric IgA1 and conglutinin binding IgA1
and IgA2. These concentrations, as well as polymeric IgA2
concentrations, were abnormally increased during mucosal
infection. The magnitudes of the IgA1 concentration changes
were greater than those of the IgA2 concentration changes.
These findings provide information on the possible link between
the clinical association of disease exacerbation associated with
infection and the immunohistological finding of mesangial poly-
meric IgA deposition in these diseases [1, 7—13, 22], as dis-
cussed below. Of course, the findings do not necessarily imply
that a mucosal associated site is the source of the polymeric IgA
or that monomeric IgA is not important in the pathogenesis of
these diseases.
The cross sectional study findings of increased concentra-
tions of PIgA in patients with IgA-related renal diseases confirm
the findings of earlier studies [14—16], and the findings of
increased concentrations of K-IgA confirm the findings of
increased IgA immune complex concentrations where conglu-
tinin was used [2, 3] or whether other methodologies were
employed [1, 4, 5]. The correlation between PIgA and K-IgA
suggest that IgA immune complexes in IgAN and HSPN
patients contain significant amounts of PIgA, as found by
Sancho et al [17]. These correlations were not found in controls,
and this indicates a qualitative difference in the nature of K-IgA
in patients with IgAN and HSPN compared to controls and
patients with DMPGN.
In the longitudinal studies performed of febrile mucosal
infections the median concentrations of PIgA in the control
group were highest one to three days following the onset of
symptoms of infection. In the HSPN and IgAN patient groups
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Table 2. Results of the comparison of PIgA concentrations from earlier time periods before or during infection, to later periods during or after
infections using the Sign test
Earlier time of
comparison PIgA assay
Later time of comparison
Controls (N = 27) Timinga IgAN group (N 21) Timinga HSPN group (N = 11) Timinga
1—3 4—6 7—10 After 1—3 4—6 7—10 After 1—3 4-6 7—10 After
Before PIgA NS 0.05 NS NS 0.01 0.01 0.01 NS 0.05 0.05 0.05 NS
infection PIgA1
PIgA2
0.01
NS
0.05
NS
NS
NS
NS
NS
0.01 0.01 0.01 NS
0.05 0.05 0.05 NS
0.01
NS
0.01
NS
0.01
NS
NS
NS
1—3 Days from PIgA NS NS NS NS 0.05 NS NS 0.05 NS
onset of PIgA1 NS NS 0.05 0,05 0.01 NS NS NS 0.05
infection PIgA2 NS NS NS NS NS 0.05 NS NS NS
4—6 Days from PIgA NS 0.05 0.01 0.01 NS 0.05
onset of PIgA1 NS 0.05 NS 0.01 NS 0.05
infection PIgA2 NS NS NS 0.05 NS NS
7—10 Days PIgA NS 0.01 0.05
from onset PIgA1 NS 0.0! 0.05
of infection PIgA2 NS 0.05 NS
Results are reported at the 0.05 and 0.01 level of confidence. NS, the result was not significant.
a Timing refers to the time at which tests were performed: 1—3, 4—6, or 7—10 days following the onset of infection or 6—12 weeks after infection.
PIgA and PIgA subclass concentrations had started to increase
one to three days following the onset of symptoms. The assays
used in these studies measure nonspecific polyclonal PIgA [23],
and there is no comparable data in the literature. Studies of
specific polymeric polyclonal antibodies have shown that fol-
lowing influenza infection [19], parenteral tetanus toxoid admin-
istration [20] or Campylobacter jejuni infection [21], specific
PIgA production was maximal one to two weeks after symp-
toms began or after immunization. The short time interval to
maximal PIgA concentrations noted in the control group in this
study may have occurred for several reasons. A latent period of
asymptomatic infection before illness notification would result
in the reported day of onset of symptoms (taken as day 1) being
later than the day of antigen exposure, whereas, in the above
studies, the time of antigen administration was known. Also,
there may be a polyclonal activation of non-specific PIgA
production induced by nonspecific mediators of inflammation.
Thus, the early changes in PIgA concentrations may not be due
to the production of specific PIgA directed toward the infective
agents. In the control group there are no later changes (that is,
at the times four to six and seven to ten days following onset of
infection) in PIgA concentrations suggestive of an increase in
specific PIgA antibody production. This is expected as PIgA
comprises 10 to 20% of total serum IgA [14—16], and the
response to any specific antigen is likely to be small in compar-
ison with the total amount of IgA present.
In contrast to controls, the PIgA2 concentrations in patients
with IgAN and HSPN started to increase by one to three days
following the onset of symptoms and PIgA concentrations were
maximal at that time, although concentrations of PIgA and
PIgA1 were maximal for at least seven to ten days, and possibly
longer, after the onset of infection. This time interval would be
consistent with the production of specific PIgA and PIgA,.
Defective clearance of PIgA could be responsible for the
increase in PIgA concentrations as the half-life of PIgA is three
days [31]. However, the clinical setting of an acute infection,
where increased antibody production is expected, makes this
less likely than increased PIgA production.
The time course of K-IgA concentrations in patients with
HSPN have been followed during the course of mucosal infec-
tion by Kaufmann et al [32], and Coppo et al [33] followed
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Fig. 4. Longitudinal study of total K-1gA (K-IgA), K-IgA,, and K-
IgA2 concentrations during a mucosal infection. The time intervals and
groups are as described for Figure 3. The horizontal line on the K-IgA2
panel represents the sensitivity of that assay.
K-IgA concentrations in patients with IgAN and HSPN during
periods of disease activity and inactivity. Both groups found
K-IgA concentrations to be increased at times of infection or
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Table 3. Results of the comparison of K-IgA concentrations from earlier time periods before or during infection to later periods during or
after infections using the Sign test
Earlier time of
comparison K-IgA assay
Later time of comparison
Controts (N 17) Timinga IgAN group (N = 21) Timinga HSPN group (N = 11) Timinga
1—3 4—6 7—10 After 1—3 4—6 7—10 After 1—3 4—6 7—10 After
Before
infection
1—3 Days from
onset of
infection
4—6 Days from
onset of
infection
7—10 Days
from onset
of infection
K-IgA
K-IgA1
K-IgA2
K-IgA
K-IgA1
K-IgA2
K-IgA
K-IgA1
K-IgA2
K-IgA
K-IgA1
K-IgA2
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
0.05
NS
NS
0.01 0.01 0.01 NS
0.01 0,01 0.01 NS
0.01 0.05 NS NS
NS NS 0.01
NS NS 0.01
NS NS 0.05
NS 0.01
0.01 0.01
NS NS
0.01
0.01
NS
NS
NS
0.05
NS
0.05
NS
NS
NS
NS
0.05
0.05
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
0.05
0.05
0.05
0.05
0.01
NS
0.01
NS
NS
Results have been reported at the 0.05 and 0.01 level of confidence. NS, results were not significant.
aTiming refers to the time at which tests were performed: 1—3, 4—6, or 7—10 days following the onset of infection or 6—12 weeks after infection.
increased disease activity as found in this study. The cause of
the slower increase in K-IgA concentration in the HSPN group
is unclear.
In the control group K-IgA concentrations increased during
infection in some patients, as reflected by the increase in the
75th percentile value (Fig. 4A) and the significant decrease in
the control concentrations between seven and ten days and 6 to
12 weeks following infection. Thus, it is possible that the
differences found in patients with IgA-related renal disease are
a quantitative exaggeration of normal changes rather than a
qualitatively different immune response.
The lack of a close correlation between PIgA and quantitated
hematuna and between K-IgA and hematuria does not imply
that glomerular damage is not associated with these two param-
eters. Indeed, over the course of mucosal infection all patients
had increased hematuria and increased concentrations of PIgA
and K-IgA. MSU RBC counts reflect the concentration of urine
as well as the amount of hematuria. K-IgA represents only a
portion of immune complexed IgA [32], and it is unlikely that a
direct correlation exists between the formation of immune
complexes, glomerular deposition of such complexes, inflam-
matory mediated defects in glomerular capillaries and red blood
cell loss proportional to the degree of glomerular damage.
However, the lack of a close correlation between these immune
parameters and hematuria is evidence that PIgA and K-IgA are
not the direct effectors of glomerular injury causing increased
hematuria in the setting of mucosal infection.
This study adds to a large literature circumstantially support-
ing muscosal immune involvement in these diseases. The vast
majority of episodes of macroscopic hematuria in these diseases
occur in association with upper respiratory or gastrointestinal
infections, and the specific etiological agents include all those
listed in Table 1 [1, 22, 34—37]. IgAN has been associated with
celiac disease [38] and dermatitis herpetiformis [39], and a
gluten free diet has been reported to result in decreased IgA
immune complex concentrations and disease activity [40].
Increases in the ratio of IgA to IgG producing cells in tonsillar
tissue have been found [41, 42] and increased salivary and
breast milk IgA concentrations have been reported [43—45].
Antigens usually associated with mucosal sites (food protein
and viral antigen) have been found in the glomerular mesangium
by some investigators [46—481, but the problem of non-specific
immunological staining has cast doubt on these reports [49]. An
animal model of IgAN induced by oral immunization has been
developed [50].
The increased concentrations of K-IgA and PIgA indicate
altered control of the IgA immune response under conditions of
antigen challenge associated with mucosal inflammation, as
well as at times of apparent freedom from infection. The
longitudinal studies demonstrating that mucosal infection was
associated with increased hematuria, increased PIgA and in-
creased K-IgA concentrations are evidence that the mucosal
immune system may be involved in the causation of these
immune abnormalities. The mucosal immune system could be
the source of the PIgA and K-IgA1; it could be the source of a
factor stimulating the systemic production of PIgA and K-IgA,
or perhaps a source of a factor inhibiting PIgA and K-IgA
clearance.
Alternatively, disordered kinetics of the IgA immune re-
sponse may be present in these diseases. Following experimen-
tally induced influenza A infection [19] or acute Campylobacter
jejuni enteritis [21], the IgA response is initially dominated by
polymeric IgA production, but later monomeric IgA production
becomes dominant. Similar changes in the predominant molec-
ular form of IgA have been described following parenteral
treatment with rabbit anti-thymocyte globulin [51] or parenteral
tetanus toxoid immunization [20]. If these kinetics represent a
generalized phenomenon in the IgA immune response, it could
be speculated that an abnormality in the switch of PIgA1
production to monomeric IgA1 production results in prolonged
PIgA1 production and thus gives rise to the abnormal magnitude
and duration of the PIgA response reported here.
IgAN and HSPN are diseases that are different clinically, but
both share a tendency for increased hematuria, often macro-
scopic in degree, to accompanying mucosal infection. In this
study, changes in the concentrations and in the time course of
changes in concentrations of PIgA and IgA immune complexes
were found in association with mucosal infection. The site of
origin of these IgA abnormalities is unknown, but the involve-
330 Jones et a!: Polymeric igA and igA immune complexes
ment of mucosal factors in the aberrant IgA immunoregulation
appears likely.
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